文献速递头痛与眩晕

乌布吉泮急性治疗轻度疼痛与中度或重度疼痛偏头痛的疗效

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
PubMed 文献 · Neurology · 2022-08-17

这是一项3期、开放标签、剂量盲法、52周延伸试验的事后分析,纳入808名成人偏头痛患者,随机分为常规治疗、乌布吉泮50mg或100mg组。分析19291次发作显示,轻度疼痛时使用乌布吉泮治疗,2小时无痛率、无伴随症状率及恢复正常功能率均显著高于中度或重度疼痛时治疗。

要点

  • 乌布吉泮50mg治疗轻度疼痛2小时无痛率47.1% vs 中度或重度疼痛23.6%(OR 2.89,95%CI 2.57-3.24)。
  • 乌布吉泮100mg治疗轻度疼痛2小时无痛率55.2% vs 中度或重度疼痛26.1%(OR 3.50,95%CI 3.12-3.92)。
  • 轻度疼痛时治疗,2小时无恐光、恐声、恶心及恢复正常功能的比例均显著更高(p<0.001)。

核心结论

  • 与中度或重度疼痛时治疗相比,轻度疼痛时使用乌布吉泮治疗可显著提高2小时无痛率、无伴随症状率及恢复正常功能率。

研究设计与样本

  • 3期、开放标签、剂量盲法、52周延伸试验的事后分析;成人偏头痛患者按1:1:1随机分为常规治疗、乌布吉泮50mg或100mg组。
  • 参与者每4周治疗最多8次任意疼痛强度的偏头痛发作;疗效结局仅收集乌布吉泮组数据。

主要发现

  • 共纳入808名参与者的19291次发作数据。
  • 乌布吉泮50mg组2小时无痛率:轻度疼痛47.1% vs 中度或重度疼痛23.6%(OR 2.89,95%CI 2.57-3.24)。
  • 乌布吉泮100mg组2小时无痛率:轻度疼痛55.2% vs 中度或重度疼痛26.1%(OR 3.50,95%CI 3.12-3.92);两种剂量p<0.0001。
  • 轻度疼痛时治疗,2小时无恐光、恐声、恶心及恢复正常功能的比例均显著更高(p<0.001,两种剂量)。
  • 最常见不良事件为上呼吸道感染(两种剂量均约11%);严重不良事件发生率乌布吉泮50mg组2%、100mg组3%。

关键数值与推荐

  • 该试验提供III级证据:轻度疼痛时使用乌布吉泮治疗较中度或重度疼痛时治疗,可提高2小时内实现无痛、无伴随症状及正常功能的可能性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To examine the efficacy of ubrogepant in the treatment of migraine with mild vs moderate or severe pain. METHODS: This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults with migraine were randomized 1:1:1 (usual care, ubrogepant 50 mg, or ubrogepant 100 mg). Participants treated up to 8 migraine attacks of any pain intensity every 4 weeks. Efficacy outcomes (only collected for ubrogepant) included 2-hour pain freedom (2hPF), freedom from associated symptoms, and from disability. A generalized linear mixed model with binomial distribution and logit link function was used to assess the influence of baseline pain intensity on treatment outcomes in this post hoc analysis. RESULTS: Data for 19,291 attacks from 808 participants were included. 2hPF rates were higher for attacks treated when pain was mild vs moderate or severe: ubrogepant 50 mg (47.1% vs 23.6%; odds ratio [95% CI] 2.89 [2.57-3.24]) and ubrogepant 100 mg (55.2% vs 26.1%; 3.50 [3.12-3.92]; p < 0.0001 both doses). Rates of freedom from photophobia, phonophobia, and nausea 2 hours after treatment were also significantly higher following the treatment of mild vs moderate or severe pain (p < 0.001 all symptoms, both doses). At 2 hours, the proportion of attacks with normal function was more than double for both doses of ubrogepant (p < 0.001). The most common adverse event was upper respiratory tract infection (∼11% both doses). Serious adverse events were reported by 2% in ubrogepant 50 mg and 3% in ubrogepant 100 mg. DISCUSSION: Relative to treatment of attacks with moderate or severe pain, treatment with ubrogepant during mild pain resulted in significantly higher rates of freedom from pain, freedom from associated symptoms, and achieving normal function 2 hours after administration. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, NCT02873221. CLASSIFICATION OF EVIDENCE: This trial provides Class III evidence that treatment of migraine with ubrogepant when pain is mild vs moderate or severe increases the likelihood of achieving pain freedom, absence of symptoms, and normal function within 2 hours postdose.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Dodick DW, Goadsby PJ, et al. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain. Neurology. 2022. PMID: 35977836. doi:10.1212/WNL.0000000000201031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。